RecruitingNCT04073966

MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

Magnetic Resonance Imaging Biomarkers for Radiation-Induced Neurocognitive Decline Following Stereotactic Radiosurgery of Newly Diagnosed Brain Metastases: An Observational Pilot Study

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment

15 participants

Start Date

Dec 4, 2019

Study Type

OBSERVATIONAL

Conditions

Brain Metastases Radiation Exposure Neurocognitive Deficit White Matter Alterations

Summary

Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. The overarching goal of this study is to better understand the determinants of RT-associated changes in white and gray matter function and associated neurocognitive decline.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at MRI brain scans to find early markers of cognitive decline (memory and thinking problems) in patients who receive stereotactic radiosurgery (SRS) — a highly focused, high-dose radiation treatment — for newly diagnosed brain metastases (cancer that has spread to the brain). **You may be eligible if...** - You have a confirmed cancer diagnosis - You have been newly diagnosed with brain metastases and are scheduled for stereotactic radiosurgery (SRS) - You are expected to live at least one year - You are 18 years or older - You can read, understand, and follow instructions in English **You may NOT be eligible if...** - You have had prior radiation to the brain or head - You have had another type of cancer in the past (other than certain common skin cancers or early cervical cancer) - You cannot provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

University of North Carolina at Chapel Hill, Department of Radiation Oncology

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04073966

Related Trials

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

NCT050459502 locations

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT046890481 location

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT074625071 location

NTS-WBRT in Brain Metastases

NCT050138921 location

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

NCT066490581 location